Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Declines By 55.4%

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totaling 752,574 shares, a decrease of 55.4% from the December 31st total of 1,689,232 shares. Approximately 2.3% of the company’s stock are short sold. Based on an average daily trading volume, of 461,342 shares, the days-to-cover ratio is presently 1.6 days. Based on an average daily trading volume, of 461,342 shares, the days-to-cover ratio is presently 1.6 days. Approximately 2.3% of the company’s stock are short sold.

VYNE Therapeutics Stock Performance

Shares of VYNE stock opened at $0.57 on Friday. The company has a market capitalization of $18.86 million, a price-to-earnings ratio of -0.73 and a beta of 1.95. VYNE Therapeutics has a one year low of $0.28 and a one year high of $2.94. The company’s 50-day moving average is $0.50 and its 200 day moving average is $0.48.

VYNE Therapeutics (NASDAQ:VYNE) last issued its earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02. The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.13 million. VYNE Therapeutics had a negative net margin of 6,425.19% and a negative return on equity of 80.84%. As a group, research analysts predict that VYNE Therapeutics will post -0.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VYNE has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen cut VYNE Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 25th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $4.50.

Institutional Trading of VYNE Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Baker BROS. Advisors LP bought a new position in shares of VYNE Therapeutics during the third quarter valued at $285,000. Adage Capital Partners GP L.L.C. lifted its stake in shares of VYNE Therapeutics by 87.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after purchasing an additional 300,000 shares during the period. Kennedy Capital Management LLC purchased a new position in shares of VYNE Therapeutics during the 2nd quarter worth $942,000. Shay Capital LLC purchased a new position in VYNE Therapeutics during the third quarter valued at $165,000. Finally, Patient Square Capital LP lifted its position in shares of VYNE Therapeutics by 23.3% during the 2nd quarter. Patient Square Capital LP now owns 317,033 shares of the company’s stock valued at $523,000 after buying an additional 60,000 shares in the last quarter. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.